InspireMD, Inc.: insider trades · United States · SEC (Form 4)

About InspireMD, Inc.

InspireMD, Inc. (Nasdaq: NSPR) is a U.S.-based medical device company focused on stroke prevention and the treatment of carotid artery disease. Headquartered in Miami, Florida, the company operates in a highly regulated medtech niche where clinical evidence, regulatory approvals, and commercial execution are central to long-term value creation. InspireMD was founded in 2005 and built its business around its proprietary MicroNet™ mesh technology, designed to reduce plaque prolapse and embolic events during carotid interventions. ([stockanalysis.com](https://stockanalysis.com/stocks/nspr/company/?utm_source=openai)) The company’s core franchise is centered on the CGuard platform, originally commercialized outside the United States and later expanded into the next-generation CGuard Prime product. InspireMD describes CGuard Prime as a mesh-covered carotid stent engineered to provide sustained embolic protection. A major inflection point came on June 24, 2025, when the FDA granted PMA approval for CGuard Prime in the United States, opening the door to a U.S. commercial launch in the company’s most strategically important market. InspireMD has also disclosed FDA IDE approval to advance the CGUARDIANS II pivotal study for the TCAR indication, which broadens the potential clinical and commercial scope of its platform. ([investors.inspiremd.com](https://investors.inspiremd.com/news-releases/news-release-details/inspiremd-announces-fda-approval-cguardr-prime-carotid-stent)) From a competitive standpoint, InspireMD is a focused, specialized player rather than a broad-based cardiovascular conglomerate. Its investment case is driven less by scale and more by technological differentiation, clinical data quality, and physician adoption. The company highlights the C-GUARDIANS study as key supporting evidence for CGuard Prime and has stated that more than 65,000 implants have been sold to date, suggesting a meaningful installed base in its historical markets. In a sector dominated by larger, better-capitalized competitors, InspireMD’s edge lies in its proprietary protection concept and the evidence base behind it. ([investors.inspiremd.com](https://investors.inspiremd.com/news-releases/news-release-details/inspiremd-announces-fda-approval-cguardr-prime-carotid-stent)) Geographically, InspireMD has historically generated most of its revenue outside the United States through distributor-led commercial activity in multiple international markets. The U.S. launch announced in July 2025 marked a strategic shift toward a more balanced geographic mix, supported by the company’s expanded Miami headquarters and operating infrastructure. This move is important because it gives the business direct access to a larger reimbursement-driven market, but it also raises the execution bar for sales force build-out, physician education, and regulatory compliance. ([stockanalysis.com](https://stockanalysis.com/stocks/nspr/company/?utm_source=openai)) Recent developments most relevant to investors include the FDA approval and U.S. launch of CGuard Prime, continued progress in the TCAR clinical pathway, and full-year 2025 results reported in March 2026 showing $9.0 million of annual revenue and $1.4 million of U.S. revenue during the first two quarters of launch. For international equity investors, InspireMD represents a Nasdaq-listed United States medtech story with meaningful clinical optionality, commercial upside from U.S. penetration, and the typical risks of an early-stage growth company, including scale-up execution and ongoing capital needs. ([nasdaq.com](https://www.nasdaq.com/press-release/inspiremd-reports-fourth-quarter-and-full-year-2025-financial-results-2026-03-18?utm_source=openai))